Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from BLUE

Bluebird Bio Joins Layoff Band Wagon As Gene Therapy Biotech Cuts Staff To Reduce Costs

Bluebird Bio Inc (NASDAQ:BLUE) is laying off about 30% of its workforce before the FDA decides the fate of two of its gene therapies. The gene therapy-focused company is showing the exit to nearly one-third of its staff to extend its cash runway into the first half of 2023 and save $160 million…

Papa John's Inks Refranchising Agreement With Sun Holdings

Papa John's Inks Refranchising Agreement With Sun Holdings

Papa John's International Inc (NASDAQ:PZZA) has re-franchised its majority stake in a joint venture between Papa Johns and Blue and Silver Ventures Ltd. The financial terms of the transaction were not disclosed. Sun Holdings, one of Papa Johns largest domestic franchise partners, has assumed control of 90 Papa Johns restaurants in Texas. Blue…

Husso to the rescue as Blues beat Canucks 4-1

ST. LOUIS — There are a lot of ways for a team to get a win in the face of a prolonged series of losses and subpar play, and the simplest is the road the Blues took on Monday: Have a goalie play a great game.

St. Louis Post-Dispatch

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Everton have extra midfield option as former defender opens up about injury 'curse'

Your morning Everton headlines as Morgan Feeney gives an exclusive interview to the ECHO and Fabian Delph hands Frank Lampard a fitness boost

bluebird bio's Return On Capital Employed Insights

According to Benzinga Pro data, during Q4, bluebird bio (NASDAQ:BLUE) posted sales of $1.61 million. Earnings were up 28.49%, but bluebird bio still reported an overall loss of $155.05 million.

Expert Ratings For bluebird bio

Within the last quarter, bluebird bio (NASDAQ:BLUE) has observed the following analyst ratings:

Why Bluebird Bio Shares Are Tumbling Today

Hit by several delays for its gene therapy programs, Bluebird bio Inc (NASDAQ: BLUE) ended 2021 with a cash and equivalents balance of

inkl

Read news from The Economist, FT, and more,
with one subscription

FDA Pushes Review Period For Bluebird bio's Neurodegenerative Disease, Thalassemia Gene Therapies

FDA Pushes Review Period For Bluebird bio's Neurodegenerative Disease, Thalassemia Gene Therapies

The 60 Best Pop Groups From the '80s, '90s, and '00s You May Have Forgotten About

The 60 Best Pop Groups From the '80s, '90s, and '00s You May Have Forgotten About

And, no, we're not counting *NSYNC.

1 … 12 13 14 15

People

Vladimir Tarasenko

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play